Analysis Expres2ion: Good potential with reduced risk

ExpreS2ion provides a platform for the production of protein suited for next-generation vaccines, including therapeutic vaccines. With a strengthened offer, license revenue with a high margin can increase. The value of the projects in the jointly owned subsidiary is not considered to be fully discounted. Read the full report here. (Swedish)